In the last trading session, 1.58 million shares of the Ginkgo Bioworks Holdings Inc (NYSE:DNA) were traded, and its beta was 1.07. Most recently the company’s share price was $6.33, and it changed around -$0.04 or -0.63% from the last close, which brings the market valuation of the company to $313.92M. DNA currently trades at a discount to its 52-week high of $75.20, offering almost -1087.99% off that amount. The share price’s 52-week low was $5.26, which indicates that the current value has risen by an impressive 16.9% since then. We note from Ginkgo Bioworks Holdings Inc’s average daily trading volume that its 10-day average is 1.52 million shares, with the 3-month average coming to 1.46 million.
Ginkgo Bioworks Holdings Inc stock received a consensus recommendation rating of Underweight, based on a mean score of 3.83. If we narrow it down even further, the data shows that 1 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended DNA as a Hold, whereas 1 deemed it a Buy, and 3 rated it as Underweight. Ginkgo Bioworks Holdings Inc is expected to report earnings per share of -1.49 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA has showed a red trend with a performance of -0.63% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 10.07 on recent trading dayincreased the stock’s daily price by 37.14%. The company’s shares are currently down -90.64% year-to-date, but still down -27.74% over the last five days. On the other hand, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is -28.72% down in the 30-day period. We can see from the shorts that 7.33 million shares have been sold at a short interest cover period of 8.73 day(s).
The consensus price target as assigned by Wall Street analysts is $6.5, which translates to bulls needing to increase their stock price by 2.62% from its current value. Analyst projections state that DNA is forecast to be at a low of $4.35 and a high of $12.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Ginkgo Bioworks Holdings Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -79.34 percent over the past six months and at a 35.77% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 66.25% in revenue this quarter, and will report an increase of 26.72% in the next quarter. The year-over-year growth rate is expected to be -9.64%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 44.43M in revenue for the current quarter. 3 analysts expect Ginkgo Bioworks Holdings Inc to make 44.47M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 34.76M and 37.94M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 27.83%. Forecasts for the next quarter put sales growth at 17.20%.
Ginkgo Bioworks Holdings Inc earnings are expected to increase by 45.22% in 2024, but the outlook is positive 31.20% per year for the next five years.
DNA Dividends
Ginkgo Bioworks Holdings Inc’s next quarterly earnings report is expected to be released in December.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.15% of Ginkgo Bioworks Holdings Inc shares, and 68.57% of them are in the hands of institutional investors. The stock currently has a share float of 73.06%. Ginkgo Bioworks Holdings Inc stock is held by 233.0 institutions, with VIKING GLOBAL INVESTORS LP being the largest institutional investor. By 2024-06-30, it held 7.1383% of the shares, which is about 143.09 million shares worth $47.83 million.
VANGUARD GROUP INC, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
